It has been a big week for Aussie investors with a large number of popular ASX shares releasing results.
Let's see what Morgans is saying about three of these shares after reviewing their results.
Image source: Getty Images
BHP Group Ltd (ASX: BHP)
Morgans was pleased with BHP's FY 2026 results, noting that it maintained a solid operating performance and benefitted from higher commodity prices.
However, due to its current valuation, the broker has downgraded BHP shares to a trim rating with a $55.30 price target. It said:
A solid FY26 result, with an upsized final dividend of US 99cps, against a share price that appears to already factor in more upside, we lower our rating to TRIM. Metal prices were a key driver, but BHP also maintained a solid operating performance on controllable factors against a tough backdrop in FY26.
CSL Ltd (ASX: CSL)
The broker notes that biotech giant CSL delivered a result broadly in line with expectations in FY 2026.
It was particularly pleased to see that immunoglobulins demand has remained strong, the Seqirus business delivered seasonal influenza vaccine growth, and cost savings ahead of target.
In response, Morgans has retained its buy rating with a $187.71 price target. It commented:
The FY26 result was broadly in line with expectations, with revenue of US$15.8bn (+3% vs guidance) and underlying NPATA of US$3.1bn. Importantly, underlying Ig demand remains strong, Seqirus delivered seasonal influenza growth despite lower US immunisation rates and transformation savings reached US$176m ahead of target, although Vifor continues to face challenges.
While FY27 targets flat top line growth, as Vifor remains a significant drag, the earnings trajectory is becoming increasingly skewed towards recovery, supported by stabilising plasma economics, cost-outs and improved commercial execution. We make modest changes to FY27-28 estimates and increase our blended DCF, PE and EV/EBITDA-based target price to A$187.71 on a multiple roll forward. BUY.
Hub24 Ltd (ASX: HUB)
Finally, Morgans was pleased with this investment platform provider's FY 2026 results.
It highlights that its EBITDA was up 30% and in line with expectations, while its net profit after tax was slightly ahead of estimates.
Following a review of the results, Morgans has retained its accumulate rating with a $92.00 price target. It said:
HUB's FY26 Group result was largely in line with expectations with underlying EBITDA of A$211.4m, up 30% on pcp, consistent with MorgansF/Consensus A$212m, and underlying NPAT of A$137.3m slightly ahead of MorgansF A$131.9m. Platform EBITDA however fell short of expectations due to slower revenue momentum in 2H26, which was outpaced by 2H26 Platform Opex growth. HUB's FY28 FUA target of A$186-200bn points to FY28 net flows of ~A$18-19bn, however momentum through to Aug'26 appears to be running behind this due to elevated discretionary gross outflows.
Whilst the timing of this roll-off remains uncertain, we see this as a near-term headwind and likely to abate, although it does suggest FY27 flows will track lower than FY26 (particularly vs. 1H26). Our EPS forecast moves by +/-1% in FY27-28F, which sees our price target revised to A$92.00/sh. We retain our Accumulate rating.
